Atypical antipsychotic usage-related higher serum leptin levels and disabled lipid profiles in euthymic bipolar patients

Neuropsychobiology

Volumn 53, Issue 2, 2006, Pages 108-112

  Gergerlioglu, H Serdar ^a   Savas, Haluk A ^a   Celik, Ahmet ^a   Savas, Esen ^b   Yumru, Mehmet ^a   Tarakcioglu, Mehmet ^a   Gergerlioglu, Nursadan ^b   Atmaca, Murad ^c  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b Av Cengiz Gokcek State Hospital   (Turkey)

^c FIRAT UNIVERSITY   (Turkey)

Author keywords

Atypical antipsychotics; Bipolar disorder; Glucose; Leptin; Lipid profiles; Mood stabilizers

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LEPTIN; LIPID; LITHIUM; LOW DENSITY LIPOPROTEIN; MOOD STABILIZER; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; VALPROIC ACID; VERY LOW DENSITY LIPOPROTEIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ARTICLE; BIPOLAR DISORDER; CHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG USE; DYSLIPIDEMIA; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BLOOD GLUCOSE; CHOLESTEROL; FEMALE; HUMANS; LEPTIN; LIPOPROTEINS; MIDDLE AGED;

EID: 33645981258     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092219     Document Type: Article

References (37)

1. Prolo P, Wong ML, Licino J: Leptin. Int J Biochem Cell Biol 1998;30:1285-1290.
2. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-432.
3. Spiegelman BM, Flier JS: Obesity and the regulation of energy balance. Cell 2001;104:531-543.
4. Sahu A: Minireview: a hypothalamic role in energy balance with special emphasis on leptin. Endocrinology 2004;145:2613-2620.
5. Elmquist JK, Elias CR, Saper CB: From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 1999;22:221-232.
6. Uehara Y, Shimizu H, Ohtani K, Sato N, Mori M: Hypothalamic corticotropin-releasing hormone is a mediator of the anorexigenic effect of leptin. Diabetes 1998;47:890-893.
7. Considine RV, Caro JF: Leptin and regulation of body weight. Int J Biochem Cell Biol 1997;29:1255-1272.
8. Watson S, Gallagher P, Ritchie JC, Ferrier IN, Young AH: Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 2004;184:496-502.
9. Deuschle M, Blum WF, Englaro P, Schweiger U, Weber B, Pflaum CD, Heuser I: Plasma leptin in depressed patients and healthy controls. Horm Metab Res 1996;28:714-717.
10. Auwerx J, Steals B: Leptin. Lancet 1998;351:737-742.
11. Zukowska-Grojec Z: Neuropeptid I: a novel sympathetic stress hormone and more. Ann NY Acad Sci 1995;771:219-233.
12. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Kennedy SH: Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord 2003;5:28-35.
13. 2 receptor (DRD2) gene. Mol Psychiatry 1996;1:325-335.
14. Ertugrul A, Meltzer HY: Antipsychotic drugs in bipolar disorder. Int J Neuropsychopharmacol 2003;6:277-284.
15. Hirschfeld RM: The efficacy of atypical antipsychotics in bipolar disorders. J Clin Psychiatry 2003;64(suppl 8):15-21.
16. Yatham LN: Efficacy of atypical antipsychotics in mood disorders. J Clin Psychopharmacol 2003;23(suppl 1):9-14.
17. Yatham LN: Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics. Bipolar Disord 2003;5(suppl 2):7-19.
18. Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L: Antipsychotics in bipolar disorders. Encephale 2004;30:417-424.
19. McCormack PL, Wiseman LR: Olanzapine: a review of its use in the management of bipolar I disorder. Drugs 2004;64:2709-2726.
20. Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, Ghaemi SN, Feldman PD, Risser RC, Evans AR, Calabrese JR: Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser vs mood stabiliser alone. Br J Psychiatry 2004;184:337-345.
21. Atmaca M, Kuloglu M, Tezcan E, Ustundag B: Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003;64:598-604.
22. McIntyre RS, Mancini DA, Basile VS, Srinivasan J, Kennedy SH: Antipsychotic-induced weight gain: bipolar disorder and leptin. Clin Psychopharmacol 2003;23:323-327.
23. Melkersson K, Dahl ML: Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004;64:701-723.
24. McIntyre RS, McCann SM, Kennedy SH: Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001;46:273-281.
25. Atmaca M, Kuloglu M, Tezcan E, Gecici O, Ustundag B: Serum cholesterol and leptin levels in patients with borderline personality disorder. Neuropsychobiology 2002;45:167-171.
26. Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Gecici O, Firidin B: Serum leptin and cholesterol values in the suicide attempters. Neuropsychobiology 2002;45:124-127.
27. Atmaca M, Kuloglu M, Tezcan E, Ustundag B: Serum cholesterol and leptin levels in patients with bipolar disorders. Neuropsychobiology 2002;46:176-179.
28. Atmaca M, Kuloglu M, Tezcan E, Gecici O, Ustundag B: Weight gain, serum leptin and triglyceride levels in the patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr Res 2003;60:99-100.
29. Kraus T, Haack M, Schuld A, Hinze-Selch D, Pollmacher T: Low leptin levels but normal body mass indices in patients with depression or schizophrenia. Neuroendocrinology 2001;73:243-247.
30. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 2004.
31. Jensen HV, Plenge P, Mellerup ET, Davidsen K, Toftegaard L, Aggernaes H, Bjorum N: Lithium prophylaxis of manic-depressive disorder: daily lithium dosing schedule versus every second day. Acta Psychiatr Scand 1995;92:69-74.
32. Dogan E, Erkoc R, Eryonucu B, Sayarlioglu H, Agargun MY: Relation between depression, some laboratory parameters, and quality of life in hemodialysis patients. Ren Fail 2005;27:695-699.
33. Kraus T, Haack M, Schuld A, Hinze-Selch D, Kuhn M, Uhr M, Pollmacher T: Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999;156:312-314.
34. Sequist TD, Bates DW, Cook EF, Lampert S, Schaefer M, Wright J, Sato L, Lee TH: Prediction of missed myocardial infarction among symptomatic outpatients without coronary heart disease. Am Heart J 2005;149:74-81.
35. Klumpers UM, Boom K, Janssen FM, Tulen JH, Loonen AJ: Cardiovascular risk factors in outpatients with bipolar disorder. Pharmacopsychiatry 2004;37:211-216.
36. Luef G, Abraham I, Hoppichler F, Trinka E, Unterberger I, Bauer G, Lechleitner M: Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism 2002;51:1274-1278.
37. Himmerich H, Koethe D, Yassuridis A, Pollmacher T: Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium. Psychopharmacology 2005;179:447-451.